OKYO Pharma (NASDAQ:OKYO) & Akari Therapeutics (NASDAQ:AKTX) Head to Head Review

OKYO Pharma (NASDAQ:OKYO) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Risk and Volatility

OKYO Pharma has a beta of 0.04, indicating that its stock price is 96% less volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for OKYO Pharma and Akari Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1	1	3	0	2.40
Akari Therapeutics	1	0	3	0	2.50

OKYO Pharma presently has a consensus price target of $5.67, suggesting a potential upside of 265.59%. Akari Therapeutics has a consensus price target of $32.33, suggesting a potential upside of 255.31%. Given OKYO Pharma’s higher probable upside, equities research analysts clearly believe OKYO Pharma is more favorable than Akari Therapeutics.

Profitability

This table compares OKYO Pharma and Akari Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Akari Therapeutics	N/A	-147.45%	-74.70%

Institutional and Insider Ownership

3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by company insiders. Comparatively, 32.2% of Akari Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares OKYO Pharma and Akari Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$8.95 million	N/A	N/A
Akari Therapeutics	N/A	N/A	-$17.30 million	N/A	N/A

Summary

OKYO Pharma beats Akari Therapeutics on 5 of the 8 factors compared between the two stocks.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.